Table 1

Clinical details of 17 subjects whose CGM data were included in the final analysis

nAge (years)SexDuration of diabetes (years)Urea (mmol/l)CVD (yes/no)*MedicationHb (g/dl)A1C (%)Time undergoing dialysis (years)Erythropoietin dose (μg/week)
153M205.1YesGliclazide, 40 mg b.i.d.13.45.11.230
259M1819.3YesGliclazide, 80 mg q.d.11.35.33.780
365M615.1YesDiet12.961.315
472M1622.3YesGliclazide, 80 mg q.d.9.963100
563M2023.0YesHumulin M3 (8 units b.i.d.)14.66.43.630
652M1828.2YesGliclazide, 40 mg b.i.d.15.16.53.730
765M2414.0YesNovoRapid (10 units a.m.), Glargine (35 units p.m.)12.16.62.860
868M2614.0YesNovoMix 30 (10 units b.i.d.)10.95.67.730
965M3017.9YesMixtard 30 (10 units, 8 units)126.75.410
1067M1824.0YesGliclazide, 40 mg b.i.d.13.16.710.260
1158F917.0NoMixtard 50 (23 units, 24 units)9.37.40.580
1253M1326.7YesGliclazide, 160 mg b.i.d.11.77.92.740
1379M2221.9YesMixtard 30 (18 units, 12 units)1486.820
1442M2616.0YesMixtard 30 (18 units, 12 units)13.48.53.915
1565F3013.2YesMixtard 30 (6 units b.i.d.)13.87.36.250
1665F414.5YesGliclazide, 160 mg b.i.d.12.48.93.330
1754F1917.8NoNovoMix 30 (16 units, 10 units)11.79.21.760
  • *Documented history of vascular disease defined as ischemic heart disease (history of myocardial infarction, revascularization procedure or angiographically proven coronary disease), cerebrovascular disease (history of cerebrovascular accident or transient ischemia attack) or peripheral vascular disease (history of amputation due to gangrene, revascularization procedure, or peripheral vascular disease proven angiographically or by Doppler ultrasonography). F, female; M, male.